PTCH1 and medulloblastoma: Characterized by developmental abnormalities and distinct postnatal cancer occurrence including medulloblastoma (1–2% of cases) and rhabdomyosarcoma (0.5% of cases), Gorlin syndrome primarily results from inactivating PTCH1 mutations on chromosome 9, leading to SMO hyperactivity [178,179,180,181,182,183].